146727-85-7

Upstream product

• 146727-84-6 benzyl (2R)-2-((1E)-3-ethoxy-3-oxoprop-1-enyl)pyrrolidine-1-carboxylate 
• 50463-82-6 (2R)-(+)-phenylmethyl 2-formylpyrrolidine-1-carboxylate 
• 501-53-1 benzyl chloroformate 
• 72597-18-3 (2R)-(+)-phenylmethyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 68832-13-3 D-prolinol 

Downstream Products

• 143321-82-8 (R)-3-(N-Benzyloxycarbonylpyrrolidin-2-ylmethyl)-5-(methylaminosulfonylmethyl)-1H-indole 
• 146727-86-8 (R)-2-{(E)-3-[(2-Bromo-4-methylsulfamoylmethyl-phenyl)-(2,2,2-trifluoro-acetyl)-amino]-propenyl}-pyrrolidine-1-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

INDANOL DERIVATIVE

The present invention provides a compound having the following general formula (I) which is useful as a neurokinin receptor antagonist: (wherein, R1, R2: optionally substituted (hetero)aryl, R3: -CO-R4, -CO-O-R4, etc., R4: alkyl, cycloalkyl, etc., A: CH2, CO, SO2, B: a single bond, etc., D: oxygen, CH2, E: alkylene, alkenylene, n: 1 to 3).

The synthesis of a conformationally restricted analog of the anti-migraine drug sumatriptan

The synthesis of 5-N-Methylaminosulfonylmethyl-3-(N-methylpyrrolidin-2-ylmethyl)indole (1), a conformationally restricted analog of the anti-migraine drug, sumatriptan, is described. To incorporate our novel stereogenic replacement for the aminoethyl side